knowledge -WSS

knowledge

author：knowledge 2025-09-03 11:52:22 - browse：32827

Micrograph of ulcerative colitis -- biotech coverage from STAT — Micrograph of chronic active ulcerative colitis in a biopsy specimen. Wikimedia Commons

Checkpoint inhibitors, drugs that unleash the immune system, have turned into blockbuster therapies that have transformed outcomes for some patients with deadly cancers. AltruBio, a Bay Area biotech, is betting it can help patients suffering from autoimmune and inflammatory diseases by taking the opposite tack: pumping the brakes on runaway immune responses.

The company on Tuesday announced that it has raised $225 million in a Series B venture round led by BVP Partners, with the biotech’s backers also including RA Capital Management, Cormorant Asset Management, and Soleus Capital. AltruBio plans to put that money toward advancing a drug that is already being tested in a mid-stage trial for ulcerative colitis, an increasingly competitive market in which a number of pharma companies have launched drugs.

It’s the latest example of intense investor interest in immunology-focused companies. Firms such as Paragon Therapeutics and Prometheus Laboratories have recently been at the center of financing mega-rounds, and Blackstone Life Sciences recently committed up to $300 million to launch Uniquity Bio, a company developing treatments for asthma and chronic obstructive pulmonary disease.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Duchenne breakthrough therapy leaves behind pioneering families
Next article： Popular nasal decongestant doesn't actually relieve congestion

focus

WSS

Future doctors need a strong humanities education

How to make the FDA’s new prescription one

What causes osteoarthritis? Researchers study link to brain protein

Prior authorization reform is both possible and imperative

Will the IRA bring competition to the biologics market?

Listen: Covid's latest surge, Alnylam at the FDA, & the end of an era

Wikipedia

knowledge

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Wikipedia

Novavax promises a turnaround & Lilly roils the obesity market

Mass General, Mayo Clinic look to monetize custom

Dobbs anniversary: the lost opportunity of abortion as health care

Hospitals consider fixing cancer drug shortages on their own

New air purifier tech could be key to improving indoor air quality

Popular nasal decongestant doesn't actually relieve congestion

Dobbs anniversary: the lost opportunity of abortion as health care

FDA proposes changes to key medical devices approval pathway

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Cardiologists urge adding sexual orientation, gender identity to health records

hotspot

Hospitals consider fixing cancer drug shortages on their own

New Covid vaccine is recommended for everyone 6 months or older

Maisha Meds is a PBM, but don't call it that

Maisha Meds is a PBM, but don't call it that

Future doctors need a strong humanities education

Mass General, Mayo Clinic look to monetize custom

knowledge

focus

knowledge

entertainment